A Phase 3 interventional study of Hyperbaric oxygen in Post-COVID-19 Syndrome, Post-COVID Syndrome and Post COVID-19 Condition, sponsored by Erasmus Medical Center. Not yet recruiting at 7 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-28.
Sponsored by Erasmus Medical Center · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Post-Acute COVID-19 Syndrome with a site in Netherlands — 6 open to participants now, 6 under way, 3 of them phase 3. Post-Acute COVID-19 Syndrome · Netherlands.
Among the 15 studies in Post-Acute COVID-19 Syndrome with a site in Netherlands, this one is one of 2 that started in 2024, is one of 3 in phase 3, and was the 8th registered.
606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.
Browse Post-Acute COVID-19 Syndrome studies →6 of the 15 studies in Post-Acute COVID-19 Syndrome with a site in Netherlands are open now. Recruiting first, the newest first:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Sites in Netherlands
Ages 18–70
Michele van Vugt · Sites in Netherlands
Ages 18–65
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Sites in Netherlands
Ages 18–65
Amsterdam UMC, location VUmc · Sites in Netherlands
Ages 18+
Janneke van de Wijgert · Sites in Netherlands
Ages 18+
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 4
First in 2020; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 60 across 417 interventional studies indexed under Post-Acute COVID-19 Syndrome.
Median enrollment 75 across the 8 interventional studies, 256 across the 7 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 15 has an industry lead sponsor. The 10 most frequent:
Erasmus Medical Center is the lead sponsor of 479 studies on the registry; 182 are open to participants now.
Erasmus Medical Center has 1 study filed under Post-Acute COVID-19 Syndrome — fewer than ten, so there is no comparison to draw.
1 of the studies in Post-Acute COVID-19 Syndrome with a site in Netherlands that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07298005Michele van VugtSonlicromanol in Post-COVID | 2027-02 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies in Post-Acute COVID-19 Syndrome with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical try is to investigate the effect of hyperbaric oxygen therapy (HBOT) on symptoms, quality of life and absence of work through sickness in patients with post-COVID on short- and mid-term, as well as to identify biochemical mechanisms of action.
The main questions it aims to answer are:
Participants will undergo 40 sessions of HBOT. Researchers will compare HBOT with standard care alone (control group). In case of a positive outcome, patients in the control group can cross-over to the HBOT group after 6 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
40 sessions of HBOT at 2.4 ATM
Drug: Hyperbaric oxygen
Hyperbaric oxygen therapy (2.4 ATA, 40 sessions)
Also known as: HBO, HBOT, Hyperbaric oxygen therapy
Physical and mental component scores of the 36-item Short Form Survey (SF-36)
Range 0-100, with higher scores indicating higher quality of life
Time frame: Week 20 (i.e. 3-months after end of HBOT)
Euroqol-5D (EQ-5D)
Descriptive for 5 dimensions + visual analogue score (VAS, range 0-100 with higher scores indicating higher quality of life)
Time frame: Week 0/4/8/20/34 (i.e. at start of HBOT, halfway during treatment, directly after treatment and 3 and 6 months after treatment).
Activity tracking (through wrist band), monitoring heart rate, step count and sleep patterns
Time frame: Worn continuously until week 34
Biochemical parameters
Time frame: Week 0, 8 and 34 (i.e. at start of HBOT, directly after HBO and 3-months after treatment)
Absence from work
Time frame: Week 0/4/8/20/34 (i.e. at start of HBOT, halfway during treatment, directly after treatment and 3 and 6 months after treatment).
Cost-effectiveness
Time frame: Week 0/4/20/34 (i.e. at start of HBOT, directly after treatment and 3 and 6 months after treatment).
Start is estimated for Oct 2024; primary completion for Oct 2025, 12 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Hyperbaric Oxygen
Post-Acute COVID-19 Syndrome →